semaglutide weight loss guidelines Dosage Chart for & Dosing Guide Semaglutide Maintenance Dose After Goal

The FDA is currently reviewing the obesity NDA with a target action date of April 10, 2026

Why this matters 1 Oral GLP-1 changes the access equation Approved in December 2025, Wegovy pill (oral semaglutide) offers a once-daily, non-injectable option for people living with obesity or overweightremoving a major barrier to long-term adherence

Survodutide : Phase 2 demonstrated up to 18.7% mean weight loss at 46 weeks with 4.8 mg dose (on-treatment analysis)

The primary OASIS 4 results, published in September in the New England Journal of Medicine , reported an average weight loss of 16.6% among participants taking the oral semaglutide